HomeCompareCTLT vs EQR

CTLT vs EQR: Dividend Comparison 2026

CTLT yields 3.15% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $16.0K in total portfolio value
10 years
CTLT
CTLT
● Live price
3.15%
Share price
$63.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$385.93
Full CTLT calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — CTLT vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTLTEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTLT + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTLT pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTLT
Annual income on $10K today (after 15% tax)
$267.80/yr
After 10yr DRIP, annual income (after tax)
$328.04/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $2,918.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTLT + EQR for your $10,000?

CTLT: 50%EQR: 50%
100% EQR50/50100% CTLT
Portfolio after 10yr
$32.5K
Annual income
$2,102.77/yr
Blended yield
6.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CTLT
Analyst Ratings
8
Buy
12
Hold
1
Sell
Consensus: Hold
Price Target
$74.25
+17.0% upside vs current
Range: $41.00 — $132.00
Altman Z
1.6
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTLT buys
0
EQR buys
0
No recent congressional trades found for CTLT or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTLTEQR
Forward yield3.15%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$24.5K$40.5K
Annual income after 10y$385.93$3,819.61
Total dividends collected$3.5K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$74.25$70.35

Year-by-year: CTLT vs EQR ($10,000, DRIP)

YearCTLT PortfolioCTLT Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,015$315.06$11,248$547.57$233.00EQR
2$12,110$324.34$12,701$666.53$591.00EQR
3$13,291$333.26$14,405$814.59$1.1KEQR
4$14,564$341.83$16,413$999.84$1.8KEQR
5$15,933$350.05$18,795$1,232.92$2.9KEQR
6$17,406$357.91$21,639$1,527.95$4.2KEQR
7$18,990$365.43$25,057$1,903.80$6.1KEQR
8$20,692$372.60$29,197$2,385.87$8.5KEQR
9$22,520$379.43$34,250$3,008.70$11.7KEQR
10$24,482$385.93$40,467$3,819.61$16.0KEQR

CTLT vs EQR: Complete Analysis 2026

CTLTStock

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Full CTLT Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CTLT vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTLT vs SCHDCTLT vs JEPICTLT vs OCTLT vs KOCTLT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.